Article Versions Notes

Eliadis P, Mais A, Papazisis A, Loxa EK, Dimitriadis A, Sarrigeorgiou I, Backovic M, Agallou M, Zouridakis M, Karagouni E, et al. Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera. Vaccines. 2024; 12(8):914. https://doi.org/10.3390/vaccines12080914

Eliadis, Petros, Annie Mais, Alexandros Papazisis, Eleni K. Loxa, Alexios Dimitriadis, Ioannis Sarrigeorgiou, Marija Backovic, Maria Agallou, Marios Zouridakis, Evdokia Karagouni, and et al. 2024. "Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera" Vaccines 12, no. 8: 914. https://doi.org/10.3390/vaccines12080914

Eliadis, P., Mais, A., Papazisis, A., Loxa, E. K., Dimitriadis, A., Sarrigeorgiou, I., Backovic, M., Agallou, M., Zouridakis, M., Karagouni, E., Lazaridis, K., Mamalaki, A., & Lymberi, P. (2024). Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera. Vaccines, 12(8), 914. https://doi.org/10.3390/vaccines12080914